Dr. Daniel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
605 Glenwood Dr
Suite 200
Chattanooga, TN 37404Phone+1 423-698-1844Fax+1 423-624-2226
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005- Duke University HospitalResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999
Certifications & Licensure
GA State Medical License 2005 - 2025
TN State Medical License 2005 - 2025
NC State Medical License 1999 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Clinical Trials
- Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsDurvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.Ying Cheng, David R Spigel, Byoung Chul Cho, Konstantin K Laktionov, Jian Fang
The New England Journal of Medicine. 2024-10-10 - 1 citationsClinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang
The Oncologist. 2024-06-03 - 2 citationsSymptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.Johan F Vansteenkiste, Jarushka Naidoo, Corinne Faivre-Finn, Mustafa Özgüroğlu, Augusto Villegas
JTO Clinical and Research Reports. 2024-03-01
Journal Articles
- Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLCDavid R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Press Mentions
Cancer Biomarker Testing: Teaming with Physicians to Ensure Access EverywhereFebruary 7th, 2023- OneOncology Adopts Slack as a Digital Headquarters for Physician CommunicationsOctober 24th, 2022
- All 14 OneOncology Partner Practices Apply to Participate in EOMOctober 3rd, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
